Biocryst Pharmaceuticals Inc

Most Recent

  • BioCryst Pharmaceuticals

    BioCryst Pharmaceuticals Stock Looks Expensive, Wait for Pullbacks

    By Ambrish Shah
  • BioCryst Pharmaceuticals

    BioCryst Stock Is Another Player in the WallStreetBets Shorted Rallies

    By Rachel Curry
  • uploads///Sarepta ana reco
    Company & Industry Overviews

    What Sarepta Therapeutics’ Valuation Trend Indicates

    Sarepta Therapeutics (SRPT) incurred a net loss of $109.27 million in the second quarter compared to a net loss of $63.05 million in Q2 2017.

    By Kenneth Smith
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.